RTOG 9802: the end of the beginning?

RTOG 9802: the end of the beginning?

Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

Low grade glioma

Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

What are the issues?

Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

R9802 SCHEMA

Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

Presented at ASCO 2008, published 2012

Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

What were the issues?

Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

ASCO 2014: Overall Survival

Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

Conclusions

Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

Three trials on adjuvant PCV chemotherapy: the anaplastic OD and LGG trials

Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

Delayed benefit of chemotherapy

Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

New WHO grading scheme?

Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

What are the unanswered questions?

Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

What are the unanswered questions?

Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

What are the unanswered questions?

Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

EORTC 22033 on RT vs TMZ in low grade glioma: PFS in relation to 1p status

Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

Slide 16

Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

2014: the role of chemotherapy established in all diffuse glioma

Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

Now what?

Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

Slide 19

Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting